Clinical trials in Saint-Malo

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Study on Tislelizumab for Elderly Patients with Advanced Esophageal Squamous Cell Carcinoma Unfit for Chemotherapy

Study on Tislelizumab for Elderly Patients with Advanced Esophageal Squamous Cell Carcinoma Unfit for Chemotherapy

Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

Study Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX

Study Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX